BioIndustry Association UK is the One Stop Shop for Global Regenerative Medicine
11/6/2013 10:57:23 AM
5 November 2013 -- The UK is the must-go-to location for regenerative medicine research and development says, "Realise Returns from the UK's regenerative medicine and cell therapy industry", a booklet published today by the BioIndustry Association (BIA).
The booklet showcases some of the leading regenerative medicine companies in the UK including ReNeuron and Cell Medica who are developing exciting and world leading approaches to stroke and cancer care respectively.
The booklet also highlights why the UK is a great place to develop regenerative medicines. Public funders have committed to provide tangible support throughout the product development pipeline via grant funding that helps leverage private investment, have introduced innovative approaches to collaborative research and development and have established the Cell Therapy Catapult. These approaches are bolstered by the underpinning infrastructure and core strengths in the research, translation and commercialisation of regenerative medicines available in the UK.
Professor Chris Mason, University College London and Chair, BIA Cell Therapy and Regenerative Medicine Advisory Committee said:
"The global cell therapy industry is at the important inflection point between spirited pioneering and true commercialisation. The UK leads the world in healthcare, finance and stem cell R&D. The integration of these major assets, combined with robust government support for regenerative medicine, makes the UK the prime location to invest in cell therapy as it rapidly grows into a multibillion pound sector on a par with pharma and biotech."
Keith Thompson, Chief Executive of the Cell Therapy Catapult, said:
"The UK continues to strengthen its position as the go-to place for turning the promise of regenerative medicine into real products with the potential to revolutionise medicine. This publication, which highlights the strength of the UK regenerative medicine infrastructure, governmental support and the quality of the cell therapy community, discusses the factors behind this position. By working with researchers, the health system and companies on the translation of promising research into commercially viable products, the Cell Therapy Catapult is helping build a pipeline of investable therapies that promise to transform patients' lives and create a new industry."
Steve Bates, BIA Chief Executive Officer, said:
"The UK is fortunate to have not only world leading research but also cutting edge companies such as those highlighted in the booklet, who are well set to deliver on the promise of regenerative medicine. In the UK, research in this key field of 21st century medicine is supported by both the government and the public. That is why I believe breakthroughs across a range of unmet medical needs including diabetes, cardiac disease, cancer, and stroke will emerge from the regenerative medicine community in the UK."
For further information, please contact Robert Winder, Head of Communications, firstname.lastname@example.org, 020 7630 2191; mobile 07825 942 934.
Realise Returns from the UK's regenerative medicine and cell therapy industry
The BIA booklet "Realise Returns from the UK's regenerative medicine and cell therapy industry" is available from the BIA website: http://bia.me/BIA_realise
The booklet was launched at a meeting at the Cell Therapy Catapult in London and at the UK Ambassador's reception for BIO Europe delegates in Vienna.
Cell Therapy Catapult
The Cell Therapy Catapult is a centre of translational excellence for cell therapy and regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery and commercialisation of cell therapy, making it a location for business start-up and growth. Based in London at Guy's Hospital, the centre takes products into early clinical trials, providing clinical, technical, manufacturing and regulatory expertise and access to the NHS. It is focused on collaboration and lowering barriers to investment and funding, and operations have grown rapidly since its inception in 2012. The global cell therapy industry was estimated to have an turnover of $1bn in 2011 and is estimated to grow to $5bn by 2014 (Mason, Regen Med 5(3) 2010; Mason, Regen Med 6(3) 2011). For more information please go to http://ct.catapult.org.uk
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Help employers find you! Check out all the jobs and post your resume.
comments powered by